UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Learn why young investors should prioritize compounding in their financial strategy. Early investments can yield significant long-term benefits.
28,299 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Forecasting Tesla is never dull. This article lays out base, bull, and bear scenarios for the next five years, with a...
Intuit has faced a sharp share-price pullback this year. This guide breaks down the why, the risk factors, and what i...
The weight loss drug space has become a focus for growth-minded investors. This guide weighs Eli Lilly's proven progr...
Stock splits have made a comeback, and some analysts link splits to meaningful upside. This guide shows how to identi...
Realty Income has built a legendary monthly dividend streak. This analysis evaluates whether the stock still makes se...
Tech stocks regain momentum as data-center spending reshapes the market. Oracle stands out as a potential upside surp...
The SEC has moved to clarify which crypto assets fall under securities rules, saying that many assets—including staki...
Two lesser-known robotics stocks beat earnings, underscoring a broader wave of AI-powered automation beyond the famil...
The data center build-out accelerating wave is reshaping where investors place bets. Beyond chips, three infrastructu...
As July begins, the crypto market today, july shows renewed strength. Bitcoin tops 60k while other assets catch a bid...
As markets shift, the question isn’t just 'do I buy index funds?'—it’s 'could picking individual stocks better positi...